|
000
| 02527cam 2200409zi 4500 |
|---|
| 001 | 9.916714 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221130092217 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 221028t20222022onc o f000 0 eng d |
|---|
| 020 | |a9780660460291 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-148/2022E-PDF |
|---|
| 245 | 00|aSummary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : |brecommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. |
|---|
| 246 | 10|aRecommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults |
|---|
| 246 | 17|aSummary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (3 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Recommandations sur l'utilisation chez les adultes du vaccin de rappel à ARNm Spikevax bivalent BA.4/5 (50 mcg) de Moderna contre la COVID-19 : résumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Pub.: 220546." |
|---|
| 520 | |a"On November 3, 2022, Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals 18 years of age and older"--Overview, page 3. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|zCanada. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|xGovernment policy|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tRésumé des mises à jour du Comité consultatif national de l'immunisation (CCNI) du 3 novembre 2022 : |w(CaOODSP)9.916716 |
|---|
| 856 | 40|qPDF|s824 KB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-148-2022-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/summary-national-advisory-committee-immunization-november-3-2022-recommendations-use-moderna-spikevax-bivalent-mrna-50-mcg-covid-19-booster-vaccine-adults.html |
|---|